Visual abstract
Introduction
- Parkinson’s disease (PD) is a degenerative neurological disorder characterized by a reduction in the number of dopaminergic neurons in the substantia nigra. This leads to motor symptoms such as gait disturbances, tremors, facial changes, and non-motor symptoms including depression [1,2]. The underlying causes of these symptoms remain unknown, and treatment involves the use of drugs to alleviate symptoms [3]. However, 10 years after starting the medication, patients often experience severe side effects, such as levodopa therapy-induced dyskinesia and off-period dyskinesia symptoms, prompting ongoing research into more fundamental treatments [3,4].
-
1. Acupuncture treatment in patients with PD
- The clinical application of acupuncture treatment for PD began in the early 1970s, when Dr. Li applied Chinese herbal drugs, acupuncture, and moxibustion. The effectiveness and efficacy of the PD drug Madopar (levodopa 50 mg and benserazide 12.5 mg, 3 to 4 times per day) alone or combining with acupuncture were reviewed by Dr. Li’s team (RCTs n = 11, patients n = 831) and indicated that the combination may improve clinical efficacy [5]. In 2008, a study by Ren showed that acupuncture combined with Madopar significantly improved treatment outcomes and reduced the dose of the drug in a study involving 50 patients with PD [6].
- Based on prior research, functional magnetic resonance imaging (fMRI) signals were measured during acupuncture at the GB34 acupoint (Yanglingquan) in patients with PD. As a result, significant changes in brain signals were observed in areas commonly impacted by PD, including the substantia nigra, caudate, thalamus, and putamen [7]. In a study conducted by Yeo et al [8], after 8 weeks of acupuncture treatment at various acupoints, including GB34, which is known to be effective in the treatment of PD [9], the total unified Parkinson’s disease rating scale (UPDRS) score, indicating the severity of PD (clinician-scored and monitored), decreased from 18 points to 9 points. This improvement was sustained during an 8-week nontreatment observation period. Other individual scores, including the UPDRS 3 motor function evaluation score, were significantly reduced by acupuncture treatment and remained low during the observation period [8]. Examination of changes in brain signals induced by acupuncture, measured by fMRI in these patients, revealed changes in signals within regions associated with PD [8]. In particular, patients with significantly lower thalamic signals showed a marked increase after acupuncture treatment compared with baseline levels, and a positive correlation was observed between their fMRI signals in the thalamus and UPDRS 3 scores [8]. Given that the thalamus is a crucial brain region for transmitting sensory and motor signals, it can be inferred that acupuncture regulates the thalamic motor nuclei, thus controlling abnormalities in the motor system in PD. Since these results were observed 8 weeks after starting acupuncture treatment, extending the duration of acupuncture could potentially reveal significant signal changes and correlations in other regions of the brain affected by PD (Figure 1).
-
2. Acupuncture stimulation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced PD mouse model
- Based on these clinical effects, changes in gene expression regulated by acupuncture were observed in a PD mouse model [10,11]. Among these genes, serum- and glucocorticoid-inducible kinase 1 (Sgk1) was identified as being involved in controlling α-synuclein, a biomarker of PD [12]. Sgk1 has been shown to have diverse cellular functions, including promoting cell survival [13–15]. Sgk1 has been reported to exhibit protective function under oxidative stress conditions [16]. A characteristic feature of neurodegenerative disorders such as PD is oxidative stress [17]. In a PD mouse model induced by MPTP, α-synuclein expression, which was elevated compared with normal mice, was regulated back to normal levels in the group receiving combined acupuncture treatment at GB34 and LR3 with MPTP (hereinafter “acupuncture group”), demonstrating a neuroprotective effect [12]. Furthermore, in the acupuncture group, the expression of Sgk1, which was reduced due to PD, was maintained at normal levels [12]. To examine the correlation between Sgk1 and α-synuclein expression, Sgk1 was knocked out of SH-SY5Y cells (a model for dopaminergic neurons) using small interference RNA targeting Sgk1. Analysis of this model revealed increased expression of α-synuclein and phosphorylated α-synuclein (at y125), both associated with the pathogenesis of PD, in Sgk1-deficient SH-SY5Y cells [12,18]. These findings indicate that changes in Sgk1 gene expression, regulated by acupuncture, are associated with PD pathogenesis. In particular, a decrease in Sgk1 could exacerbate PD, but acupuncture could control this deterioration at the gene expression level, demonstrating a neuroprotective effect.
- Among the intensification of research efforts related to the gut-brain axis as a method to identify causes and develop treatments for PD [19,20], gastrointestinal symptoms and changes in α-synuclein expression have been reported to influence the pathogenesis of PD [21,22]. PD mouse model data has revealed that Sgk1 expression, regulated by acupuncture, was markedly reduced in the intestines of the PD-induced group compared with normal mice [23]. A reduction in Sgk1 was associated with an increase in α-synuclein in the intestines [23]. These findings suggest that Sgk1, a PD-related factor that responds to acupuncture, could play a role in the pathogenesis or exacerbation of PD.
- Additionally, genes involved in the neuroprotective mechanisms of acupuncture can serve as foundational data to identify treatment targets and uncover the underlying causes of PD. Therefore, the evaluation of acupuncture treatment should go beyond simple efficacy tests. Examining the roles of responsive genes and biomarkers is essential, as it significantly enhances the research value of acupuncture by identifying potential treatment targets and the underlying causes of PD.
Conclusion
- Research into the mechanisms underlying the efficacy of acupuncture treatment in patients with PD has indicated that biomarkers responsive to acupuncture may be factors related to PD regulation. As research into mechanisms beyond the effects of acupuncture intensifies, acupuncture can be used as a methodology to develop treatments and investigate the fundamental causes of diseases. Therefore, there is a compelling need to revitalize research areas using acupuncture therapy as a means to explore the root causes or treatment options for various conditions, including PD.
Article information
-
Conflicts of Interest
The author has no conflicts of interest to declare.
-
Funding
None.
-
Ethical Statement
This research did not involve any human or animal experiments.
Data Availability
All relevant data are included in this manuscript.
Figure 1
Research flowchart for acupuncture in PD treatment.
PD = Parkinson’s disease.
References
- [1] Birkmayer W, Weiler G. On the pathogenesis of Parkinson’s disease. Nervenarzt 1957;28(2):53−6.PubMed
- [2] Leenders KL, Oertel WH. Parkinson’s disease: clinical signs and symptoms, neural mechanisms, positron emission tomography, and therapeutic interventions. Neural Plast 2001;8(1–2):99−110.ArticlePubMedPMCPDF
- [3] Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet 2004;363(9423):1783−93.ArticlePubMed
- [4] Prasad EM, Hung SY. Current therapies in clinical trials of Parkinson’s disease: a 2021 update. Pharmaceuticals (Basel) 2021;14(8):717. ArticlePubMedPMC
- [5] Liu H, Chen L, Zhang Z, Geng G, Chen W, Dong H, et al. Effectiveness and safety of acupuncture combined with Madopar for Parkinson’s disease: a systematic review with meta-analysis. Acupunct Med 2017;35(6):404−12.ArticlePubMedPDF
- [6] Ren XM. Fifty cases of Parkinson’s disease treated by acupuncture combined with madopar. J Tradit Chin Med 2008;28(4):255−7.ArticlePubMed
- [7] Yeo S, Lim S, Choe IH, Choi YG, Chung KC, Jahng GH, et al. Acupuncture stimulation on GB34 activates neural responses associated with Parkinson’s disease. CNS Neurosci Ther 2012;18(9):781−90.ArticlePubMedPMC
- [8] Yeo S, van den Noort M, Bosch P, Lim S. A study of the effects of 8-week acupuncture treatment on patients with Parkinson’s disease. Medicine (Baltimore) 2018;97(50):e13434. ArticlePubMedPMC
- [9] Choi YG, Yeo S, Hong YM, Lim S. Neuroprotective changes of striatal degeneration-related gene expression by acupuncture in an MPTP mouse model of Parkinsonism: microarray analysis. Cell Mol Neurobiol 2011;31(3):377−91.ArticlePubMedPDF
- [10] Yeo S, Choi YG, Hong YM, Lim S. Neuroprotective changes of thalamic degeneration-related gene expression by acupuncture in an MPTP mouse model of parkinsonism: microarray analysis. Gene 2013;515(2):329−38.ArticlePubMed
- [11] Yeo S, An KS, Hong YM, Choi YG, Rosen B, Kim SH, et al. Neuroprotective changes in degeneration-related gene expression in the substantia nigra following acupuncture in an MPTP mouse model of Parkinsonism: Microarray analysis. Genet Mol Biol 2015;38(1):115−27.ArticlePubMedPMC
- [12] Yeo S, Lim S. Acupuncture inhibits the increase in alpha-synuclein by modulating SGK1 in an MPTP induced parkinsonism mouse model. Am J Chin Med 2019;47(3):527−39.ArticlePubMed
- [13] Schoenebeck B, Bader V, Zhu XR, Schmitz B, Lubbert H, Stichel CC. Sgk1, a cell survival response in neurodegenerative diseases. Mol Cell Neurosci 2005;30(2):249−64.ArticlePubMed
- [14] Stichel CC, Schoenebeck B, Foguet M, Siebertz B, Bader V, Zhu XR, et al. sgk1, a member of an RNA cluster associated with cell death in a model of Parkinson’s disease. Eur J Neurosci 2005;21(2):301−16.ArticlePubMed
- [15] Lang F, Strutz-Seebohm N, Seebohm G, Lang UE. Significance of SGK1 in the regulation of neuronal function. J Physiol 2010;588(Pt 18):3349−54.ArticlePubMedPMC
- [16] Nasir O, Wang K, Foller M, Gu S, Bhandaru M, Ackermann TF, et al. Relative resistance of SGK1 knockout mice against chemical carcinogenesis. IUBMB Life 2009;61(7):768−76.ArticlePubMed
- [17] Radi E, Formichi P, Battisti C, Federico A. Apoptosis and oxidative stress in neurodegenerative diseases. J Alzheimers Dis 2014;42:Suppl 3. S125−52.ArticlePubMed
- [18] Yeo S, Sung B, Hong YM, van den Noort M, Bosch P, Lee SH, et al. Decreased expression of serum- and glucocorticoid-inducible kinase 1 (SGK1) promotes alpha-synuclein increase related with down-regulation of dopaminergic cell in the Substantia Nigra of chronic MPTP-induced Parkinsonism mice and in SH-SY5Y cells. Gene 2018;661:189−95.ArticlePubMed
- [19] Dogra N, Mani RJ, Katare DP. The gut-brain axis: two ways signaling in parkinson’s disease. Cell Mol Neurobiol 2022;42(2):315−32.ArticlePubMedPDF
- [20] Bonaz B. The gut-brain axis in Parkinson’s disease. Rev Neurol (Paris) 2024;180(1–2):65−78.ArticlePubMed
- [21] Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 2015;14(6):625−39.ArticlePubMed
- [22] Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. Neurobiol Dis 2012;46(3):559−64.ArticlePubMed
- [23] Seo MH, Kwon D, Kim SH, Yeo S. Association between decreased SGK1 and increased intestinal alpha-synuclein in an MPTP mouse model of Parkinson’s disease. Int J Mol Sci 2023;24(22):16408. PubMedPMC
Citations
Citations to this article as recorded by